Pharmacognosy intro
Arnica montana L. (Asteraceae), commonly known as mountain arnica, leopard's bane, or mountain tobacco, is a perennial herb native to European mountain meadows at elevations of 500 to 2,500 meters across the Alps, Pyrenees, Carpathians, and Scandinavia. The flower heads (capitula) are the primary medicinal material. Wild populations of A. montana are declining and the species is protected in many European countries; the North American species A. chamissonis is used as a commercial substitute. Arnica is restricted to topical use on intact skin. Internal administration of crude herbal preparations is toxic. The principal pharmacological actives are sesquiterpene lactones (SLs), specifically helenalin and 11alpha,13-dihydrohelenalin esters. The alpha-methylene-gamma-butyrolactone moiety of helenalin is critical to its mechanism of action. Additional constituents include flavonoids (hispidulin, spinacetin, patuletin, jaceidin, kaempferol glycosides), an essential oil rich in thymol and thymol derivatives (up to 40% of the oil fraction), phenolic acids (chlorogenic acid, caffeic acid), inulin-type fructans in the rhizome, and trace coumarins. Helenalin concentration varies significantly by geographic origin and harvest timing, as documented by Sharma et al. (2015, Journal of the Science of Food and Agriculture). Helenalin's anti-inflammatory mechanism is unusually precise. It selectively alkylates the p65 subunit of NF-kB through a covalent Michael addition reaction, preventing nuclear translocation and blocking transcription of pro-inflammatory genes including TNF-alpha, IL-1beta, IL-6, iNOS, and COX-2. Helenalin also inhibits IKK-beta kinase activity upstream of NF-kB. The anti-edema effect involves inhibition of histamine release from mast cells, inhibition of serotonin release from platelets (reducing vascular permeability), and reduced thromboxane B2 production (anti-platelet aggregation). Lass et al. (2008, Experimental Dermatology) established the dual role of SLs: anti-inflammatory at therapeutic concentrations via NF-kB suppression, but cytotoxic at higher concentrations. This defines the narrow therapeutic window that governs all clinical arnica use. Kucera et al. (2011, Pain Research and Treatment) demonstrated that topical arnica gel showed comparable efficacy to ibuprofen 5% gel for pain and function in hand osteoarthritis over 21 days, with non-inferiority for grip strength and pain VAS scores. Additional clinical evidence supports use for post-surgical bruising (rhinoplasty, facelift), post-exercise delayed onset muscle soreness, sports injuries, and post-procedural swelling after dental extraction. All applications are topical only. Internal toxicity is significant: helenalin is cardiotoxic and hepatotoxic, with ingestion causing gastroenteritis, tachycardia, cardiac arrhythmia, muscular weakness, and potentially death.